NZ569813A - Solid dispersion comprising an active ingredient having a low melting point and an absorbent, and a tablet for oral administration comprising same - Google Patents
Solid dispersion comprising an active ingredient having a low melting point and an absorbent, and a tablet for oral administration comprising sameInfo
- Publication number
- NZ569813A NZ569813A NZ569813A NZ56981306A NZ569813A NZ 569813 A NZ569813 A NZ 569813A NZ 569813 A NZ569813 A NZ 569813A NZ 56981306 A NZ56981306 A NZ 56981306A NZ 569813 A NZ569813 A NZ 569813A
- Authority
- NZ
- New Zealand
- Prior art keywords
- tablet
- solid dispersion
- fused solid
- pharmaceutically acceptable
- active ingredient
- Prior art date
Links
- 239000007962 solid dispersion Substances 0.000 title claims abstract description 58
- 239000004480 active ingredient Substances 0.000 title claims abstract description 44
- 238000002844 melting Methods 0.000 title description 13
- 230000008018 melting Effects 0.000 title description 12
- 230000002745 absorbent Effects 0.000 title 1
- 239000002250 absorbent Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 25
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 18
- HEFNNWSXXWATRW-JTQLQIEISA-N dexibuprofen Chemical compound CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 claims abstract description 18
- 229960003428 dexibuprofen Drugs 0.000 claims abstract description 14
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 14
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000008187 granular material Substances 0.000 claims abstract description 10
- 229960001680 ibuprofen Drugs 0.000 claims abstract description 10
- 238000010438 heat treatment Methods 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 238000001816 cooling Methods 0.000 claims abstract description 3
- 238000001035 drying Methods 0.000 claims abstract description 3
- 238000010298 pulverizing process Methods 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 57
- 238000013270 controlled release Methods 0.000 claims description 46
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- 150000005846 sugar alcohols Chemical class 0.000 claims description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 229920003169 water-soluble polymer Polymers 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 5
- 239000000811 xylitol Substances 0.000 claims description 5
- 235000010447 xylitol Nutrition 0.000 claims description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 5
- 229960002675 xylitol Drugs 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 4
- -1 sucrose fatty acid ester Chemical class 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229920001353 Dextrin Chemical class 0.000 claims description 3
- 239000004375 Dextrin Chemical class 0.000 claims description 3
- 229920000161 Locust bean gum Polymers 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 3
- 239000008119 colloidal silica Substances 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 235000010420 locust bean gum Nutrition 0.000 claims description 3
- 239000000711 locust bean gum Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims description 2
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 229940049654 glyceryl behenate Drugs 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 229940057948 magnesium stearate Drugs 0.000 claims description 2
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims description 2
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 93
- 238000007922 dissolution test Methods 0.000 description 27
- 238000000338 in vitro Methods 0.000 description 20
- 238000004090 dissolution Methods 0.000 description 17
- 229940079593 drug Drugs 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 238000007906 compression Methods 0.000 description 13
- 239000003463 adsorbent Substances 0.000 description 12
- 230000006835 compression Effects 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 12
- 239000006185 dispersion Substances 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000011978 dissolution method Methods 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- 239000000454 talc Substances 0.000 description 6
- 229910052623 talc Inorganic materials 0.000 description 6
- 235000012222 talc Nutrition 0.000 description 6
- 239000012085 test solution Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000000977 initiatory effect Effects 0.000 description 4
- 239000007970 homogeneous dispersion Substances 0.000 description 3
- 229920001800 Shellac Polymers 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000005422 blasting Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 229940009868 aluminum magnesium silicate Drugs 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- MYRTYDVEIRVNKP-UHFFFAOYSA-N divinylbenzene Substances C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229910001701 hydrotalcite Inorganic materials 0.000 description 1
- 229960001545 hydrotalcite Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940031702 hydroxypropyl methylcellulose 2208 Drugs 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940102098 revolution Drugs 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229960004029 silicic acid Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20050124386 | 2005-12-16 | ||
| PCT/KR2006/005526 WO2007069874A1 (en) | 2005-12-16 | 2006-12-18 | Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ569813A true NZ569813A (en) | 2011-07-29 |
Family
ID=38163142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ569813A NZ569813A (en) | 2005-12-16 | 2006-12-18 | Solid dispersion comprising an active ingredient having a low melting point and an absorbent, and a tablet for oral administration comprising same |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20080292702A1 (enExample) |
| EP (1) | EP1968542B1 (enExample) |
| JP (1) | JP2009519326A (enExample) |
| CN (1) | CN101330904B (enExample) |
| AU (1) | AU2006325658B2 (enExample) |
| BR (1) | BRPI0619868A8 (enExample) |
| CA (1) | CA2633266C (enExample) |
| ES (1) | ES2429097T3 (enExample) |
| IL (1) | IL191804A0 (enExample) |
| NO (1) | NO339674B1 (enExample) |
| NZ (1) | NZ569813A (enExample) |
| RU (1) | RU2403013C2 (enExample) |
| WO (1) | WO2007069874A1 (enExample) |
| ZA (1) | ZA200806138B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06002731A (es) | 2003-09-11 | 2006-06-05 | Xenoport Inc | Tratamiento y/o prevencion de incontinencia urinaria utilizando profarmacos de analogos de gaba. |
| KR101005391B1 (ko) * | 2008-07-22 | 2010-12-30 | 한국콜마 주식회사 | 덱시부프로펜 함유 서방출성 시럽제 및 그의 제조방법 |
| KR101067224B1 (ko) * | 2008-07-22 | 2011-09-22 | 한국콜마 주식회사 | 이부프로펜 함유 서방출성 시럽제 및 그의 제조방법 |
| CN101961306B (zh) * | 2009-07-24 | 2011-11-09 | 北京化工大学 | 一种低熔点药物固体分散体的制备方法 |
| CN102144982B (zh) * | 2011-03-30 | 2012-12-12 | 江苏神龙药业有限公司 | 一种米诺膦酸片及其制备方法 |
| CN102406940B (zh) * | 2011-11-01 | 2013-07-03 | 温州大学 | 一种纳米级片状羧甲基淀粉钠在固体分散体中的应用 |
| WO2013154511A1 (en) * | 2012-04-13 | 2013-10-17 | Mahmut Bilgic | Film tablet formulations comprising dexibuprofen |
| UY36046A (es) | 2014-03-26 | 2015-10-30 | Millennium Pharm Inc | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso |
| JP6647902B2 (ja) * | 2015-10-30 | 2020-02-14 | 株式会社ファンケル | 徐放性顆粒剤 |
| CN106265522A (zh) * | 2016-08-30 | 2017-01-04 | 铜陵翔宇商贸有限公司 | 布洛芬‑pvp共沉淀物及其制备方法 |
| JP7147262B2 (ja) * | 2017-05-23 | 2022-10-05 | 大正製薬株式会社 | 固形製剤 |
| JP7109255B2 (ja) * | 2017-05-23 | 2022-07-29 | ライオン株式会社 | 粉砕物の製造方法及び錠剤の製造方法 |
| EP3658123A4 (en) * | 2017-07-24 | 2021-04-28 | Acryspharm LLC | PHARMACEUTICAL COMPOSITIONS WITH A HIGH DRUG LOAD |
| RU2685294C1 (ru) * | 2018-05-10 | 2019-04-17 | Общество с ограниченной ответственностью "ДИНОН" (ООО "ДИНОН") | Поглотитель, способ его приготовления (варианты) и способ удаления диоксида углерода из газовых смесей |
| CN112263567B (zh) * | 2020-10-19 | 2022-05-03 | 南京易亨制药有限公司 | 一种布洛芬缓释胶囊及制备方法 |
| CN117363320B (zh) * | 2023-12-07 | 2024-02-13 | 黑龙江省鑫博鑫交通科技有限公司 | 一种公路用融雪剂及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56120616A (en) * | 1980-02-27 | 1981-09-22 | Kaken Pharmaceut Co Ltd | Ibuprofen-containing granule, its preparation, and internal medicine comprising it |
| GB8601204D0 (en) * | 1986-01-18 | 1986-02-19 | Boots Co Plc | Therapeutic agents |
| CH669523A5 (enExample) * | 1986-06-25 | 1989-03-31 | Mepha Ag | |
| US4806359A (en) * | 1987-04-22 | 1989-02-21 | Mcneilab, Inc. | Iburprofen sustained release matrix and process |
| DE19509807A1 (de) * | 1995-03-21 | 1996-09-26 | Basf Ag | Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen |
| IE80467B1 (en) * | 1995-07-03 | 1998-07-29 | Elan Corp Plc | Controlled release formulations for poorly soluble drugs |
| US6391338B1 (en) * | 1995-09-07 | 2002-05-21 | Biovail Technologies Ltd. | System for rendering substantially non-dissoluble bio-affecting agents bio-available |
| DE19536394A1 (de) * | 1995-09-29 | 1997-04-03 | Basf Ag | Feste Arzneiformen, erhältlich durch Extrusion einer Isomalt enthaltenden Polymer-Wirkstoff-Schmelze |
| DE69739165D1 (de) * | 1996-07-08 | 2009-01-29 | Penwest Pharmaceuticals Co | Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe |
| US6787157B1 (en) * | 1998-03-10 | 2004-09-07 | Abbott Laboratories | Multiphase active ingredient-containing formulations |
| US6183779B1 (en) * | 1999-03-22 | 2001-02-06 | Pharmascience Inc. | Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin |
| RU2246294C2 (ru) * | 1999-12-09 | 2005-02-20 | Дзе Бутс Компани ПЛС | Терапевтические средства |
| GB0113839D0 (en) * | 2001-06-07 | 2001-08-01 | Boots Co Plc | Therapeutic agents |
-
2006
- 2006-12-18 AU AU2006325658A patent/AU2006325658B2/en not_active Ceased
- 2006-12-18 CA CA2633266A patent/CA2633266C/en not_active Expired - Fee Related
- 2006-12-18 ZA ZA200806138A patent/ZA200806138B/xx unknown
- 2006-12-18 WO PCT/KR2006/005526 patent/WO2007069874A1/en not_active Ceased
- 2006-12-18 US US12/097,299 patent/US20080292702A1/en not_active Abandoned
- 2006-12-18 NZ NZ569813A patent/NZ569813A/en not_active IP Right Cessation
- 2006-12-18 ES ES06824193T patent/ES2429097T3/es active Active
- 2006-12-18 RU RU2008129041/15A patent/RU2403013C2/ru not_active IP Right Cessation
- 2006-12-18 EP EP06824193.4A patent/EP1968542B1/en not_active Not-in-force
- 2006-12-18 JP JP2008545503A patent/JP2009519326A/ja active Pending
- 2006-12-18 CN CN2006800474904A patent/CN101330904B/zh not_active Expired - Fee Related
- 2006-12-18 BR BRPI0619868A patent/BRPI0619868A8/pt not_active IP Right Cessation
-
2008
- 2008-05-29 IL IL191804A patent/IL191804A0/en unknown
- 2008-07-15 NO NO20083151A patent/NO339674B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006325658A1 (en) | 2007-06-21 |
| EP1968542A4 (en) | 2010-06-02 |
| CA2633266C (en) | 2011-08-02 |
| IL191804A0 (en) | 2008-12-29 |
| JP2009519326A (ja) | 2009-05-14 |
| HK1126671A1 (en) | 2009-09-11 |
| NO339674B1 (no) | 2017-01-23 |
| AU2006325658B2 (en) | 2010-04-08 |
| RU2403013C2 (ru) | 2010-11-10 |
| BRPI0619868A2 (pt) | 2011-10-25 |
| ZA200806138B (en) | 2009-11-25 |
| CA2633266A1 (en) | 2007-06-21 |
| BRPI0619868A8 (pt) | 2016-06-07 |
| ES2429097T3 (es) | 2013-11-13 |
| CN101330904B (zh) | 2012-04-18 |
| RU2008129041A (ru) | 2010-01-27 |
| EP1968542A1 (en) | 2008-09-17 |
| EP1968542B1 (en) | 2013-08-14 |
| NO20083151L (no) | 2008-09-05 |
| WO2007069874A1 (en) | 2007-06-21 |
| US20080292702A1 (en) | 2008-11-27 |
| CN101330904A (zh) | 2008-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ569813A (en) | Solid dispersion comprising an active ingredient having a low melting point and an absorbent, and a tablet for oral administration comprising same | |
| JP4969104B2 (ja) | 多孔質セルロース凝集体及びその成型体組成物 | |
| WO2006115198A1 (ja) | 多孔質セルロース凝集体及びその成型体組成物 | |
| JP7586523B2 (ja) | 改善されたブロモクリプチン製剤 | |
| KR20130041144A (ko) | 데페라시록스의 경구투여용 제제 | |
| Kim et al. | Modulation of the clinically accessible gelation time using glucono-d-lactone and pyridoxal 5′-phosphate for long-acting alginate in situ forming gel injectable | |
| Karavas et al. | Hydrophilic matrices as carriers in felodipine solid dispersion systems | |
| US12427113B2 (en) | Cellulose composition, tablet, and orally disintegrating tablet | |
| JP6744518B1 (ja) | セルロース組成物及び錠剤 | |
| CN1235576C (zh) | 阿魏酸钠的缓释剂型及其制备方法 | |
| EP3488869A1 (en) | Composition for solid preparation comprising hydroxypropyl methyl cellulose, solid preparation, and method for producing the same | |
| WO2005013954A1 (en) | Modified release venlafaxine hydrochloride tablets | |
| CN108785268A (zh) | 一种盐酸索他洛尔制剂及其制备方法 | |
| JP5290198B2 (ja) | ホットメルト顆粒化潤滑剤を含んでなる医薬組成物 | |
| Al-Mahmood et al. | Formulation and characterization of floating biphasic tablet consisting of cefdinir nanosuspension | |
| JP2008526719A (ja) | 高圧処理により持続性放出制御型の固形医薬組成物を製造する方法 | |
| CN112168796A (zh) | 双相缓释系统控制释放的药物缓释制剂及其制备方法 | |
| CA3158393C (en) | Cellulose composition, tablet, and orally disintegrating tablet | |
| MX2008007665A (en) | Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same | |
| HK1126671B (en) | Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same | |
| Singh et al. | Development of lipid micromatrices based sustained release tablets of glipizide: suitability of stearic acid as release retardant | |
| CN120676932A (zh) | 贝祖拉替尼制剂 | |
| KR20240025595A (ko) | 고형제의 멜라토닌 제제 | |
| CN115813873A (zh) | 一种替米沙坦片及其制备方法 | |
| Turner | Polymorphism of Polymeric Drug Excipients at High Pressure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: HANMI HOLDINGS CO., Free format text: OLD OWNER(S): HANMI PHARM. CO., LTD. |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 18 DEC 2016 BY EARN PTY LTD Effective date: 20131009 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 DEC 2017 BY EARN PTY LTD Effective date: 20160928 |
|
| LAPS | Patent lapsed |